Stocks with analyst upgrades and strong upside potential to watch now

 Bullish.Bets
 
  Bullish.Bets
 
Follow  Message
 
 
 
Bullish.Bets focuses on stocks poised for explosive moves up or down, scanning volatility, catalysts, and sentiment shifts to uncover high-impact trading opportunities
 

•  05 May 2026
 

$NVDA $196.50 Target $900 +356%
NVIDIA sits at $196.50, well below its 52-week high of $216.83 but holding cleanly above its 20-day, 50-day, and 200-day moving averages at $191.76, $187.85, and $183.05 respectively. That kind of stacked support is not noise. RSI at 50.99 shows a stock in uptrend without any overbought reading, and volume at 105.67 million shares is running below the 155.69 million average, suggesting the move has not been chased. Evercore ISI has a $900 price target on the name, implying 356% upside from current levels. The AI infrastructure buildout driving that target is grounded in actual hyperscaler capex, not speculation, and NVIDIA sits at the center of it. The noise in this ticker feed about the Meta trial is a sector distraction. The NVIDIA story is about chips and the demand for them has not slowed.

$LLY $988.87 Target $1,400 +42%
Eli Lilly delivered Q1 2026 revenue of $19.8 billion, up 56% year over year, beating consensus by 11%. Non-GAAP EPS of $8.55 topped the $6.79 estimate by 26%. Mounjaro contributed $8.66 billion in the quarter, up 125% year over year, while Zepbound added $4.16 billion in US sales. CEO David Ricks raised full-year 2026 revenue guidance to $82 billion to $85 billion and non-GAAP EPS guidance to $35.50 to $37. Barclays analyst Emily Field responded by lifting her price target to $1,400 from $1,350, keeping an Overweight rating. The FDA approval of Foundayo, the only GLP-1 pill that can be taken any time of day without food or water restrictions, adds another commercial pillar. At $988.87, the stock trades at a forward P/E of 28x with RSI at 61.61 and price above all key moving averages. The 42% gap to the Barclays target reflects a business that is compounding faster than the market is currently pricing.

$ON $102.70 Target $125 +22%
ON Semiconductor received price target increases from five major firms on May 5. KeyBanc led at $125 from $75 with an Overweight rating, followed by Susquehanna at $120 from $100, Bank of America at $115 from $85, JPMorgan at $100 from $70, and Goldman Sachs at $80 from $60. The shared thesis is that management has identified a cyclical bottom, with AI datacenter demand guided to double year over year in 2026. Lead times, book-to-bill, and backlog are all trending positively according to KeyBanc. The company posted FY2025 revenue of $6 billion and record free cash flow of $1.42 billion, and announced a $6 billion buyback. The stock has rallied sharply in recent weeks and RSI at 79.44 flags overbought conditions. The KeyBanc target still implies 22% upside, but investors entering here need to be mindful that a significant portion of the cyclical recovery has already been priced in. The GaN power device roadmap for AI datacenters is credible and the long-term setup is intact, but entry timing matters at this RSI level.

$PINS $22.28 Target $23–$38
Pinterest reported Q1 2026 sales up 18% year over year, with Q2 revenue guidance coming in above the $1.11 billion Wall Street was projecting. Seven firms raised their price targets on the same day, with Goldman Sachs going to $28 from $22, TD Cowen to $38 from $36, Barclays to $27 from $25, Bank of America to $28 from $19, Citi to $25 from $19, JPMorgan to $25 from $20, and Piper Sandler to $26 from $21. Goldman cited resilience in lower-funnel advertising, SMB and mid-market strength, AI-driven ad automation, and an increased pace of share repurchases. The stock was up 11% intraday on the news, trading near $22.28 with RSI at 73.02. At that level the average upgrade target is only marginally above current price, which is the honest constraint here. Four of the seven upgrading firms stayed at Neutral ratings. The Q1 beat was real, the AI ad improvement is real, but the near-term upside to target is thin after the move.

$NOW $92.01 Target $134–$195 +46%+
ServiceNow delivered Q1 2026 subscription revenue of $3.671 billion with a 32% operating margin, 44% free cash flow margin, and a 97% renewal rate. CEO Bill McDermott raised the Now Assist 2026 revenue target to $1.5 billion from $1 billion, and customers spending over $1 million on Now Assist grew over 130% year over year. Barclays raised its price target to $134 from $132 with an Overweight rating. J.P. Morgan carries a $195 target. The stock trades at $92.01, below both its 20-day moving average of $95.94 and its 50-day of $103.07, and RSI at 45.11 reflects weak near-term momentum. The downtrend in price action is the genuine complication for short-term positioning. For investors who focus on fundamentals, the gap between what this business is producing and what the stock is currently doing is worth taking seriously. ServiceNow is delivering measurable AI revenue at scale. The tape has not confirmed it yet.

$CRSP $52.38 Target $83 +65%
CRISPR Therapeutics received a price target cut to $83 from BofA, but the rationale was valuation, not a change in the underlying thesis. At $52.38, the stock sits below its 200-day moving average of $56.33 and well off its 52-week high of $78.48. RSI at 50.17 places it in pure sideways territory technically. The 65% gap to the BofA target is meaningful, but investors need to weigh that against the binary nature of biotech pipeline events. Volume at 3.09 million shares is running above the 1.65 million average, which signals some accumulation interest at current levels. For investors with tolerance for biotech-style volatility and a longer time horizon, the asymmetry at current prices is worth monitoring.

$BA $224.38 Target $295 +31%
Boeing received a price target raise to $295 from Tigress Financial. At $224.38, the stock trades above its 20-day moving average of $217.19, its 50-day of $221.19, and its 200-day of $219.88, which together paint a picture of gradual stabilization after years of operational turbulence. RSI at 52.10 is neutral. Volume at 3.03 million is running at roughly half the 6.16 million average, which tells you conviction is not high on either side of the trade. The 31% upside to the Tigress target is the math of a turnaround story in progress, not a momentum setup. Investors who believe delivery rates are normalizing and the defense backlog holds will find the setup compelling. Those looking for near-term price velocity will find more urgency elsewhere on this list.

$SOPH $5.07 Target $8 +55%
SOPHiA GENETICS received a price target raise to $8 from $7 at BTIG, which maintained a Buy rating following investor meetings with company leadership. The firm reported Q4 EPS of negative 28 cents versus negative 23 cents a year earlier, while revenue rose to $21.7 million from $17.7 million. Performance was driven by 45% year-over-year growth in North America and 32% growth in Asia Pacific. Full-year 2025 revenue increased 19%, and for 2026 the company guided revenue of $92 million to $94 million, above consensus estimates of $76.47 million, representing 20% to 22% growth year over year. RSI at 51.89 with an uptrend designation and volume essentially in line with average at 93,660 shares versus the 92,900 average makes this a quieter setup than the larger names. The 55% upside to the BTIG target is substantial for a small-cap cloud health analytics platform that is showing genuine commercial traction.

View all market intelligence →